This profile was last updated on // .
Is this you? Claim your profile.
Executive Advisory Board Member
Synopsis: April 2000
Barry Freehill, also a community member, presented a concept sheet at the March SAC/CAB for a randomized, controlled trial to determine if continuing 3TC when switching to a new HAART regimen in patients with the M184V mutation is associated with a slower rate of development of resistance and virologic failure as compared to not continuing 3TC when switching to a new HAART regimen.
Sports and Orthopaedic Specialists P.A
Wake Forest University
The Earnings Scout LLC
Robert W. Baird & Co.
Northwestern Mutual Wealth Management Company